Literature DB >> 32829444

Medical treatment of tuberous sclerosis-related epilepsy.

Shimrit Uliel-Sibony1,2, Veronika Chernuha3, Hadas Meirson3, Aviva Fattal-Valevski3.   

Abstract

Epilepsy is one of the most frequent CNS manifestations of tuberous sclerosis, and for most patients, it is the major debilitating factor. In up to 70% of the cases, the epilepsy is refractory and usually associated with significant behavioral as well as developmental consequences. Therefore, controlling seizures is one of the biggest medical and surgical challenges. Understanding the cellular mechanism involved in the disease empowered targeted research aimed toward early intervention in the epileptogenicity process. In this review, we present an update on the pharmacological treatments in tuberous sclerosis-related epilepsy.

Entities:  

Keywords:  Drug therapy; Epilepsy; Tuberous sclerosis

Mesh：

Year:  2020        PMID： 32829444     DOI： 10.1007/s00381-020-04772-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN： 0256-7040            Impact factor:   1.475


  55 in total

1.  Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis.

Authors:  Raffaella Cusmai; Romina Moavero; Roberta Bombardieri; Federico Vigevano; Paolo Curatolo
Journal:  Epilepsy Behav       Date:  2011-12       Impact factor: 2.937

Review 2.  Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.

Authors:  Paolo Curatolo; Rima Nabbout; Lieven Lagae; Eleonora Aronica; Josè Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna C Jansen; Floor Jansen; Katarzyna Kotulska; Romina Moavero; Finbar O'Callaghan; Antigone Papavasiliou; Michal Tzadok; Sergiusz Jóźwiak
Journal:  Eur J Paediatr Neurol       Date:  2018-05-24       Impact factor: 3.140

3.  Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex.

Authors:  Fatou Aw; Isabelle Goyer; Marie-Josée Raboisson; Christine Boutin; Philippe Major; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2016-11-23       Impact factor: 1.655

4.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Authors:  Orrin Devinsky; J Helen Cross; Linda Laux; Eric Marsh; Ian Miller; Rima Nabbout; Ingrid E Scheffer; Elizabeth A Thiele; Stephen Wright
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

5.  Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome.

Authors:  Clara W T Chung; John A Lawson; Vanessa Sarkozy; Kate Riney; Orli Wargon; Antonia W Shand; Stephen Cooper; Harrison King; Sean E Kennedy; David Mowat
Journal:  Pediatr Neurol       Date:  2017-05-26       Impact factor: 3.372

Review 6.  Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.

Authors:  Paolo Curatolo
Journal:  Pediatr Neurol       Date:  2014-11-20       Impact factor: 3.372

7.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  John J Bissler; J Christopher Kingswood; Elżbieta Radzikowska; Bernard A Zonnenberg; Michael Frost; Elena Belousova; Matthias Sauter; Norio Nonomura; Susanne Brakemeier; Petrus J de Vries; Vicky H Whittemore; David Chen; Tarek Sahmoud; Gaurav Shah; Jeremie Lincy; David Lebwohl; Klemens Budde
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

8.  Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.

Authors:  James J Collins; Cynthia Tudor; Jennifer M Leonard; Gail Chuck; David Neal Franz
Journal:  J Child Neurol       Date:  2006-01       Impact factor: 1.987

9.  The natural history of epilepsy in tuberous sclerosis complex.

Authors:  Catherine J Chu-Shore; Philippe Major; Susana Camposano; David Muzykewicz; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2009-12-22       Impact factor: 5.864

10.  Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.

Authors:  Paolo Curatolo; David N Franz; John A Lawson; Zuhal Yapici; Hiroko Ikeda; Tilman Polster; Rima Nabbout; Petrus J de Vries; Dennis J Dlugos; Jenna Fan; Antonia Ridolfi; Diana Pelov; Maurizio Voi; Jacqueline A French
Journal:  Lancet Child Adolesc Health       Date:  2018-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.